U.S. Solicitor General Noel Francisco is siding with the drug company and together they will tell the justices Jan. 7 that the Food and Drug Administration prevented Merck from changing its Fosamax label to include a warning about atypical femoral fractures.
Atypical femoral fractures are breaks that happen without impact.
The FDA’s rejection of Merck’s proposed label ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.